G1 Therapeutics

205 articles about G1 Therapeutics

• COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  7/13/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the China National Medical Products Administration (NMPA) has conditionally approved COSELA (trilaciclib hydrochloride for injection), which was jointly developed for use in Greater China by Simcere and G1 Therapeutics.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 01, 2022

  7/1/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 40,400 shares of G1’s common stock and 26,800 restricted stock units to six hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

  6/28/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors.

• G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

  6/13/2022

  G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a commercial-stage oncology company, today announced that the last patient has been randomized in the Phase 3 clinical trial of trilaciclib for patients with metastatic colorectal cancer (mCRC) receiving chemotherapy (PRESERVE 1).

• Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy

  6/2/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), today announced results of a post-hoc study analysis showing that ES-SCLC patients who received trilaciclib prior to chemotherapy had a lower incidence of single- and multilineage myelosuppressive events—fewer cases of severe neutropenia, severe anemia, and severe thrombocytopenia—compared to patients receiving placebo.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022

  6/1/2022

  G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 1,400 shares of G1’s common stock and 800 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal

  5/20/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that it received Triangle Business Journal's 2022 Company of the Year award, one of two such awards presented at the 2022 Life Sciences Award ceremony.

• G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference

  5/18/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that Jack Bailey, G1’s Chief Executive Officer, will provide a virtual corporate presentation during the H.C. Wainwright & Co. Global Investment Conference.

• G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights

  5/4/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the first quarter ended March 31, 2022.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2022

  5/2/2022

  G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for an aggregate of 63,500 shares of G1’s common stock and an aggregate of 38,000 restricted stock units to six hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022

  4/21/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2022 on Wednesday, May 4, 2022 at 8:30 a.m. ET.

• G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

  4/6/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that Jack Bailey and Raj Malik, M.D., G1’s Chief Executive Officer and Chief Medical Officer, respectively, will participate in a fireside chat during the 21st Annual Needham Virtual Healthcare Conference.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022

  4/1/2022

  G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for an aggregate of 25,800 shares of G1’s common stock and an aggregate of 11,200 restricted stock units to four hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy

  3/31/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer.

• G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference

  3/1/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming investor conferences in March 2022.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2022

  3/1/2022

  G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for an aggregate of 10,800 shares of G1’s common stock and an aggregate of 8,800 restricted stock units to four hired employees under the G1 Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive Plan.

• 

  Global Players Making Waves in MDD, Sanfilippo syndrome and SCLC

  2/24/2022

  Biopharma companies are continuously working to test new treatments to the market. Here are three clinical updates announced this week, spanning three different continents.

• G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

  2/23/2022

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2021.

• G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022

  2/9/2022

  G1 Therapeutics, Inc. will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2021 on Wednesday, February 23, 2022 at 8:30 a.m. ET.

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2022 - Feb 01, 2022

  2/1/2022

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 166,700 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc.